399 related articles for article (PubMed ID: 18437602)
1. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
2. [New indications for thalidomide?].
Tuinmann G; Hegewisch-Becker S; Hossfeld DK
Dtsch Med Wochenschr; 2001 Oct; 126(42):1178-82. PubMed ID: 11607859
[No Abstract] [Full Text] [Related]
3. Immunological effects of thalidomide and its chemical and functional analogs.
Dredge K; Marriott JB; Dalgleish AG
Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319
[TBL] [Abstract][Full Text] [Related]
4. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
5. [The revival of thalidomide: an old drug with new indications].
Laffitte E
Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
7. Palliative oncology: thalidomide.
Prommer EE
Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
[TBL] [Abstract][Full Text] [Related]
8. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide: dual benefits in palliative medicine and oncology.
Davis MP; Dickerson ED
Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide: from teratogen to anti-angiogenic.
Grover JK; Vats K
Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
[TBL] [Abstract][Full Text] [Related]
11. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide makes a comeback.
Dodd-Butera T; Broderick M
RN; 2003 May; 66(5):32-5; quiz 36. PubMed ID: 12778690
[No Abstract] [Full Text] [Related]
13. Dermatologic and nondermatologic uses of thalidomide.
Nasca MR; Micali G; Cheigh NH; West LE; West DP
Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
15. [An old drug as a carcinostatic. The new career of thalidomide].
Holzgrabe U
Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in solid tumours: the resurrection of an old drug.
Sleijfer S; Kruit WH; Stoter G
Eur J Cancer; 2004 Nov; 40(16):2377-82. PubMed ID: 15519508
[TBL] [Abstract][Full Text] [Related]
17. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
Borges Lde G; Frõehlich PE
Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Ladizinski B; Shannon EJ; Sanchez MR; Levis WR
J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538
[TBL] [Abstract][Full Text] [Related]
19. A review of thalidomide's history and current dermatological applications.
Perri AJ; Hsu S
Dermatol Online J; 2003 Aug; 9(3):5. PubMed ID: 12952752
[TBL] [Abstract][Full Text] [Related]
20. Dermatologic therapeutics: thalidomide. A practical guide.
Rosenbach M; Werth VP
Dermatol Ther; 2007; 20(4):175-86. PubMed ID: 17970884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]